PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Cost reduction while AXSM shows 12.95% growth. Joel Greenblatt would examine competitive advantage.
41.00%
Gross profit growth exceeding 1.5x AXSM's 25.15%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-31.86%
R&D reduction while AXSM shows 7.08% growth. Joel Greenblatt would examine competitive risk.
-15.50%
G&A reduction while AXSM shows 13.83% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.75%
Operating expenses reduction while AXSM shows 48.45% growth. Joel Greenblatt would examine advantage.
-27.36%
Total costs reduction while AXSM shows 46.52% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Both companies reducing D&A. Martin Whitman would check industry patterns.
28.32%
EBITDA growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
27.93%
Operating income growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-5.21%
Other expenses reduction while AXSM shows 7.27% growth. Joel Greenblatt would examine advantage.
29.77%
Pre-tax income growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
128.31%
Tax expense growth while AXSM reduces burden. John Neff would investigate differences.
29.77%
Net income growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
30.61%
EPS growth while AXSM declines. John Neff would investigate advantages.
30.61%
Diluted EPS growth while AXSM declines. John Neff would investigate advantages.
2.13%
Share count reduction below 50% of AXSM's 0.45%. Michael Burry would check for concerns.
2.13%
Diluted share reduction below 50% of AXSM's 0.45%. Michael Burry would check for concerns.